Valproic Acid CYP2C9 Hepatotoxicity Risk Calculator

Assess valproate hepatotoxicity risk from CYP2C9 metabolizer status, age under 2 years, and polypharmacy with enzyme inducers.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Assess valproate hepatotoxicity risk from CYP2C9 metabolizer status, age under 2 years, and polypharmacy with enzyme inducers

Each component has a specific meaning:

  • CYP2C9 metabolizer status — The cyp2c9 metabolizer status recorded for the scenario being assessed.
  • Age under 2 years — The age under 2 years recorded for the scenario being assessed.
  • Polypharmacy — The polypharmacy recorded for the scenario being assessed.

Note: Interpret the valproate hepatotoxicity result against the thresholds and context described above.

How to Use

Enter the CYP2C9 metabolizer status, age under 2 years, polypharmacy for the scenario you are assessing. Assess valproate hepatotoxicity risk from CYP2C9 metabolizer status, age under 2 years, and polypharmacy with enzyme inducers. Use the valproate hepatotoxicity result to inform your calculation.

Related Calculators

Phenytoin CYP2C9

Medical Ultra-depth

CBZ Autoinduction

Medical Ultra-depth

Frequently Asked Questions